Search

Memorial Sloan Kettering Cancer Center (MSK) has announced that Debra Berns has been named as MSK’s Senior Vice President and Chief Risk Officer following an extensive national search.

… Wednesday, April 18, 2018 Memorial Sloan Kettering Cancer Center (MSK) has announced that Debra Berns has been named as MSK’s Senior Vice President and Chief Risk Officer following an extensive national search. Ms. Berns will oversee MSK’s compliance, conflict of interest, and internal audit functions

… Monday, June 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:  Brendan Camellato Named a 2025 Jane Coffin Childs Fund for Medical Research Fellow Brendan Camellato, PhD , Brendan Camellato postdoctoral research scholar, was selected for the

The breakthrough gives an unprecedented look at the varied and shifting poses of a protein in action.

… Monday, June 10, 2019 Summary Scientists at the Sloan Kettering Institute have combined biochemical and computational methods to visualize how an important cancer-related protein changes shape during a chemical reaction. The results will aid drug design. A goal of chemical biology is to characterize

Spinal metastasis is one of the main causes of morbidity in cancer patients, but despite recent studies showing the major benefits of rehabilitation in these cases, oncology teams often remain unclear on how and when to utilize these services.

… Wednesday, February 15, 2017 Spinal metastasis is one of the main causes of morbidity in cancer patients, leading to pain, fracture, mechanical instability, or neurological deficits such as paralysis and bowel and bladder dysfunction. But despite recent studies showing the clear benefits of rehabilitation

Third-year students Nicholas Gauthier and Karen Hunter have been named the first Grayer Fellows at Gerstner Sloan Kettering.

… Friday, October 9, 2009 Third-year students Nicholas Gauthier and Karen Hunter have been named the first Grayer Fellows at Gerstner Sloan Kettering. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former

Learn why a new finding suggests that men with advanced prostate cancer should be screened for gene mutations.

… Wednesday, July 6, 2016 Summary Inherited mutations in DNA-repair genes, such as the BRCA genes , can increase cancer risk. A new study shows that DNA-repair mutations are significantly more common in men with metastatic prostate cancer compared with men whose prostate cancer hasn’t spread. This suggests

Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients.

… Tuesday, December 11, 2012 Summary Methods to generate stem cells have given scientists new ways to study some diseases and identify potential drugs, and could one day be used to rebuild diseased or damaged tissues in patients. On December 10, John B. Gurdon of the University of Cambridge and Shinya

Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated.

… Wednesday, July 2, 2014 Summary Understanding tumor heterogeneity may be the next big quest in cancer science, as differences between cells within a tumor can have important consequences for how cancers are diagnosed and treated. Every person’s cancer develops and grows in its own way and is unique in

In honor of Women's History Month, meet the scientific hero who helped build MSK's molecular biology program.

… Wednesday, March 13, 2019 Ora Rosen Ora Rosen, an expert in insulin signaling, co-founded the Molecular Biology Program at the Sloan Kettering Institute. Ora Rosen Dr. Rosen (right) with graduate students Roman Herrera and Lilli Petruzzelli Summary In honor of Women’s History Month, we’re remembering

Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.

… Tuesday, December 1, 2009 Summary Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments. Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after